INVESTOR DEADLINE: Olo Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – OLO

PR Newswire

SAN DIEGO, Sept. 28, 2022 /PRNewswire/ — The law firm ofRobbins Geller Rudman & Dowd LLP announces that purchasers of Olo Inc. (NYSE: OLO) Class A common stock between August 11, 2021 and August 11, 2022, inclusive (the “Class Period”) have until November 25, 2022 to seek appointment as lead plaintiff in the Olo class action lawsuit.  Captioned Pompano Beach Police and Firefighters’ Retirement System v. Olo Inc., No. 22-cv-08228 (S.D.N.Y.), the Olo class action lawsuit charges Olo and certain of its top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Olo class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-olo-inc-class-action-lawsuit-olo.html

You can also contact attorney J.C. Sanchez
of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]

CASE ALLEGATIONS: Olo provides software to restaurants to assist with online ordering and food-delivery coordination.  On February 12, 2020, Olo announced a partnership with Subway® restaurants to enable Subway’s more than 20,000 U.S.-based restaurants to handle digital orders from third-party “marketplaces” such as Uber Eats or DoorDash.  Olo then went public via an initial public offering (“IPO”) in March 2021, offered its shares for sale at $25 per share, and opened trading at $32 per share.

But as the Olo class action lawsuit alleges, defendants throughout the Class Period misled investors as to Olo’s success by citing active locations figures that included Subway locations that would imminently cease using Olo’s services and by failing to disclose that Subway would be ending its relationship with Olo.

On August 11, 2022, Olo revealed that 2,500 Subway locations had begun to directly integrate with third-party marketplaces and that the remaining 15,000 Subway locations would be removed from Olo’s active locations count in the fourth quarter of 2022 and the first quarter of 2023.  Olo further acknowledged that the previously undisclosed Subway exodus had been known internally throughout the Class Period.  In fact, Olo’s CFO, defendant Peter J. Benevides, admitted that Olo took the undisclosed pending Subway departure into account when providing guidance for the year.  On this news, the price of Olo common stock fell by approximately 36%, damaging investors.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Olo Class A common stock during the Class Period to seek appointment as lead plaintiff.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the Olo class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the Olo class action lawsuit.  An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Olo class action lawsuit. 

ABOUT ROBBINS GELLER: Robbins Geller is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases.  The Firm is ranked #1 on the 2021 ISS Securities Class Action Services Top 50 Report for recovering nearly $2 billion for investors last year alone – more than triple the amount recovered by any other plaintiffs’ firm.  With 200 lawyers in 9 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig.  Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices. 

Contact:

Robbins Geller Rudman & Dowd LLP
655 W. Broadway, Suite 1900, San Diego, CA  92101
J.C. Sanchez, 800-449-4900
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-deadline-olo-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit–olo-301634835.html

SOURCE Robbins Geller Rudman & Dowd LLP

AM Best Affirms Credit Ratings of First American Title Insurance Group Members and First American Financial Corporation

AM Best Affirms Credit Ratings of First American Title Insurance Group Members and First American Financial Corporation

OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “a” (Excellent) of First American Title Insurance Company (Omaha, NE) and its title affiliates, which are referred to as First American Title Insurance Group (FATIG). In addition, AM Best has affirmed the Long-Term ICR of “bbb” (Good) of the parent holding company, First American Financial Corporation (FAF) (Delaware) [NYSE: FAF]. The outlook of these Credit Ratings (ratings) is stable. (See below for a detailed listing of the companies and ratings.)

The ratings reflect FATIG’s balance sheet strength, which AM Best assesses as strongest, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management.

FATIG maintains a solid market position within the U.S. title insurance industry as its second-largest underwriter, based on 2021 direct premiums written. Policies are distributed on a direct basis and through a network of independent agents. The group invests heavily in its title plant, which is one of the most comprehensive in the industry. The group’s operating results have generally been in line with the title industry composite averages and supportive of surplus growth. FATIG benefits from a strong franchise value, financial flexibility and operational support from FAF, which maintains relatively modest financial leverage and solid interest coverage.

The FSR of A (Excellent) and the Long-Term ICRs of “a” (Excellent) have been affirmed with stable outlooks for the members of First American Title Insurance Group:

  • First American Title Insurance Company
  • First American Title Insurance Company of Australia Pty Limited
  • First American Title Insurance Company of Louisiana
  • First European Title Insurance Company Limited
  • First Title Insurance plc
  • Ohio Bar Title Insurance Company

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2022 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Kourtnie Beckwith

Financial Analyst

+1 908 439 2200, ext. 5124

[email protected]

Fred Eslami

Associate Director

+1 908 439 2200, ext. 5406

[email protected]

Christopher Sharkey

Manager, Public Relations

+1 908 439 2200, ext. 5159

[email protected]

Al Slavin

Communications Specialist

+1 908 439 2200, ext. 5098

[email protected]

KEYWORDS: Nebraska New Jersey Europe United States North America

INDUSTRY KEYWORDS: Banking Professional Services Insurance Finance

MEDIA:

Logo
Logo

lululemon Studio, a New Fitness Platform, Launches on October 5th

lululemon Studio, a New Fitness Platform, Launches on October 5th

Membership offers guests freedom to choose across a variety of workouts at home and in person with top trainers and premium partners

NEW YORK–(BUSINESS WIRE)–
lululemon athletica inc. (NASDAQ: LULU) today unveiled lululemon Studio, a new service connecting members to the most dynamic fitness content, community and products—at home, in person and on the go. lululemon Studio will launch on October 5th and will be accessible through the lululemon Studio Mirror, app and in-person experiences. The platform builds upon more than 10,000 on demand and live-streamed classes that have been available with a MIRROR subscription, and adds a breadth of content from some of the most notable fitness and wellness partners across North America.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005228/en/

Today in New York, lululemon revealed lululemon Studio, a new fitness platform, launching on October 5th. (Photo: Business Wire)

Today in New York, lululemon revealed lululemon Studio, a new fitness platform, launching on October 5th. (Photo: Business Wire)

lululemon Studio members will have access to some of the most sought-after studios online and in person from AARMY, Y7 Studio, DOGPOUND, FORWARD__Space, Pure Barre, Rumble, AKT and YogaSix. Members will be able to stream new weekly classes from these partners as well as sign up for discounted classes in person at the studios’ brick-and-mortar locations, in addition to receiving discounts on lululemon product, early access to lululemon events, and more.

“Our guests’ fitness needs have evolved and lululemon Studio is solving for them by providing members with access to fitness content from our world-class trainers and studio partners at home, on the go and live in studios around North America. lululemon Studio unlocks the versatility our community has told us they are looking for now. No longer will you have to choose between going to your favorite studio or streaming a class at home—you can have both,” said Nikki Neuburger, Chief Brand Officer, lululemon.

The new programming and partnerships speak to lululemon’s success building community and innovating fitness experiences in line with consumers’ changing needs, and marks the next chapter for MIRROR as it evolves to become part of lululemon Studio.

“MIRROR has always been one of the most flexible platforms that can adapt to changing fitness trends. With lululemon Studio, we’re expanding our offering to solve for our guests’ needs, extending our relationships with new studio partners and our ambassadors to add hundreds of hours of content in one place, while providing access to in-person studio classes for the ultimate hybrid experience,” said Michael Aragon, Chief Executive Officer, lululemon Digital Fitness. “We see lululemon Studio as being the daily go-to destination for experiencing the most dynamic content from the industry’s top trainers and studios, covering a range of fitness genres for all levels.”

Also launching on October 5th is the new lululemon Membership program. All lululemon guests in North America are invited to sign up for a lululemon Essential Membership for free. This program enhances the guest experience by unlocking shopping perks, community experiences, and access to select lululemon Studio classes at no cost. Members also get early access to product drops, receipt-free returns in store, and more.

lululemon Studio Membership is the pinnacle expression of the new membership program, providing members with the most immersive experience, including:

  • All the lululemon Essential Membership benefits
  • Unlimited access to content from lululemon Studio and its partners
  • 10% off lululemon purchases*
  • Special discounts to attend in-person classes at lululemon Studio partner locations
  • Unlimited access to classes held in lululemon experiential stores, as well as additional benefits

lululemon Studio Membership is available for $39 USD/month and requires the lululemon Studio Mirror. With today’s reveal, lululemon also announced it will be offering the lululemon Studio Mirror for a special price of $795 USD** and free delivery as of October 5th. Existing MIRROR members will automatically become lululemon Studio members, unlocking more value at the same monthly price.

For more information, visit www.lululemon.com/Studio

*Up to a maximum of $5,000 per year before taxes and discount. Eligible for lululemon Studio Mirror hardware account holders only.

**Full price last offered October 4, 2022.

About lululemon athletica inc.

lululemon athletica inc. (NASDAQ:LULU) is a technical athletic apparel, footwear and accessories company for yoga, running, training, and most other activities, creating transformational products and experiences that build meaningful connections, unlocking greater possibility and wellbeing for all. Setting the bar in innovation of fabrics and functional designs, lululemon works with yogis and athletes in local communities around the world for continuous research and product feedback. For more information, visit lululemon.com.

Tatiana Jovic

Senior Director, Global PR

lululemon

[email protected]

Nick Nelson

Senior Vice President

Edelman

[email protected]

KEYWORDS: United States North America Canada New York

INDUSTRY KEYWORDS: Sports Other Retail Online Retail General Sports Family Specialty Consumer Other Sports Fashion Teens Retail Other Consumer Women

MEDIA:

Photo
Photo
Today in New York, lululemon revealed lululemon Studio, a new fitness platform, launching on October 5th. (Photo: Business Wire)
Photo
Photo
Today in New York, lululemon revealed lululemon Studio, a new fitness platform, launching on October 5th. (Photo: Business Wire)

Expedia Group Launches Open World™ Accelerator to Unlock Innovation in the Travel Industry and Empower Startups to Build New Capabilities on its Platform

Expedia Group Launches Open World™ Accelerator to Unlock Innovation in the Travel Industry and Empower Startups to Build New Capabilities on its Platform

SEATTLE–(BUSINESS WIRE)–
Today, Expedia Group launches Open World™ Accelerator, an initiative that builds on its Open World vision to power partners of all sizes with the technology and supply needed to thrive in the travel market. This new initiative is designed to advance innovation in the travel industry, by supporting startups and small and medium sized business (SMBs) to fast-track their growth and innovate on Expedia’s purpose-built technology platform.

Aimed at entrepreneurs globally, the first program launching today focuses on empowering startups and SMBs working to increase access for underserved travelers, tying into Expedia Group’s Open World™ social impact and sustainability strategy and focus on democratizing the travel economy. Next year, Open World Accelerator initiative will launch an additional program focused on co-developing new capabilities.

“Travel is an economic driver for many communities around the world, but it’s a complex industry to enter and to innovate scalable products that address specific traveler needs. This is why our Open World vision is so critical to our desire to put the traveler first,” said Archana Arunkumar, Senior Vice President of Platform. “Expedia Group’s mission is to power travel for everyone, everywhere. Open World Accelerator is specifically designed to drive innovation in the industry, remove barriers to travel, and enable startups and SMBs to build capabilities on Expedia’s Open World™ technology platform that significantly improve the experience for every traveler.”

How the program works

The first Open World Accelerator program focuses on startups and SMBs working on making the travel industry more open and accessible. Each program will include a six-month curriculum for selected companies, providing them with a wide range of resources to speed up their growth. This includes business and technology development support, access to Expedia Group and wider travel industry experts for mentorship and coaching, participation in industry networking events, access to Expedia Group platform and products, and a non-equity grant.

How to apply

Start-ups and SMBs globally are welcome to apply online to join the first Open World Accelerator program from today until 21st October if they meet the following criteria:

  • Working to make the travel industry more open and accessible
  • Currently have at least a minimum viable product (MVP)
  • Were founded less than 10 years ago

A judging panel from across Expedia Group will review the applications to select the participating companies, who will then join the program kick starting in January 2023.

For more information on Open World Accelerator program, including how to apply and terms and conditions, please visit: www.expediagroup.com/open-world-accelerator

About Expedia Group

Expedia Group, Inc. companies power travel for everyone, everywhere through our global platform. Driven by the core belief that travel is a force for good, we help people experience the world in new ways and build lasting connections. We provide industry-leading technology solutions to fuel partner growth and success, while facilitating memorable experiences for travelers. Our organization is made up of three pillars: Expedia Product & Technology, focused on the group’s product and technical strategy and offerings; Expedia Brands, housing all our consumer brands; and Expedia for Business, consisting of business-to-business solutions and relationships throughout the travel ecosystem. The Expedia Group family of brands includes: Expedia®, Hotels.com®, Expedia® Partner Solutions, Vrbo®, trivago®, Orbitz®, Travelocity®, Hotwire®, Wotif®, ebookers®, CheapTickets®, Expedia Group™ Media Solutions, CarRentals.com™, and Expedia Cruises™.

For more information, visit www.expediagroup.com. Follow us on Twitter @expediagroup and check out our LinkedIn www.linkedin.com/company/expedia/.

© 2022 Expedia, Inc., an Expedia Group Company. All rights reserved. Trademarks and logos are the property of their respective owners. CST: 2029030-50

Siarah Khan

[email protected]

+44 (0) 772 528 9317

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Technology Professional Services Small Business Other Travel Transportation Lodging Destinations Vacation Tourist Attractions Travel Cruise Apps/Applications Business Software Networks Start-Up Internet

MEDIA:

Logo
Logo

Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study

  • Confirmed partial response in fourth-line metastatic pancreatic cancer patient, who had previously failed chemotherapy and checkpoint inhibitor therapy, supports MDNA11’s single-agent potential in advanced solid tumors unresponsive to established treatments

  • The observed tumor control rate of 36% in the low and mid-dose cohorts (n=14) in patients with advanced metastatic cancer further enhances our confidence in MDNA11’s monotherapy activity, consistent with our belief in its potential to selectively bolster cancer-fighting immune cells

  • Fifth dose-escalation cohort is currently enrolling patients with no dose-limiting toxicities observed in the trial to-date

TORONTO and HOUSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced new clinical data on anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11, the Company’s “beta-only” long-acting IL-2 super-agonist. These data include a confirmed partial response (PR) in a fourth-line metastatic pancreatic ductal adenocarcinoma (PDAC) patient that had previously failed chemo and checkpoint inhibitor therapies. The confirmatory scan for this patient continues to show further tumor reduction compared to prior scans, suggesting durable anti-cancer activity following MDNA11 monotherapy. Overall, five of fourteen evaluable patients in the ABILITY study’s low and mid-stage dose escalation cohorts have achieved tumor control (PR or stable disease (SD)) with MDNA11 monotherapy.

“We are excited to report confirmation of a partial response in a patient with late-stage pancreatic cancer, one of the most aggressive tumors that rarely responds to single agent immunotherapy,” said Fahar Merchant, PhD, President and CEO of Medicenna. “Furthermore, four additional patients have experienced tumor control despite the advanced stage of cancer in all patients enrolled in ABILITY’s dose escalation cohorts. This outcome provides early evidence supporting our belief in MDNA11’s single-agent anti-tumor activity and underscores its therapeutic potential as a best-in-class IL-2 agonist. Given that the dose-escalation portion of the trial is designed primarily to evaluate the safety and pharmacokinetics and determine the phase 2 dose, these early signs of potential clinical benefit are particularly impressive as we continue to dose escalate and advance towards the trial’s dose expansion phases early next year.”

The ABILITY study’s dose escalation cohorts are evaluating MDNA11 monotherapy administered intravenously once every two weeks to patients with advanced solid tumors, with the primary objective of evaluating the safety and pharmacokinetics and determining the recommended Phase 2 dose (RP2D). Once the RP2D has been established, a key secondary objective of the trial will be to evaluate the anti-tumor activity of MDNA11 alone and in combination with the checkpoint inhibitor KEYTRUDA® (pembrolizumab) in the trial’s dose expansion phases.

The ABILITY study’s first three dose escalation cohorts evaluated MDNA11 at doses of 3,10 and 30 µg/kg. Patients in the fourth and fifth dose escalation cohorts receive two 30 µg/kg “priming” doses of MDNA11 before stepping up to receive fixed doses of 60 and 90 µg/kg, respectively. The trial is currently enrolling patients in the fifth dose-escalation cohort, with no dose-limiting toxicities, dose interruptions, dose de-escalations, or treatment discontinuations due to safety issues observed to-date. A summary of demographic and therapeutic activity data from all evaluable patients in the first four dose escalation cohorts is provided below.


Patient Demographics

Prior to enrolment in the ABILITY Study, patients in Cohorts 1 to 4 (n=14) had failed up to four lines of systemic therapy.

Prior to enrolment in the ABILITY Study, eleven of fourteen patients (89%) in Cohorts 1 to 4 had relapsed on, could not tolerate, or did not respond to at least one immunotherapy with a checkpoint inhibitor.


Therapeutic Activity

Five of fourteen evaluable patients (36%) have achieved tumor control as defined in the study

  • One fourth-line (4L) metastatic PDAC patient that had previously failed chemo and checkpoint inhibitor therapies achieved a confirmed PR at the 60 µg/kg dose
  • One 3L non-clear cell renal cell carcinoma patient at the 60 µg/kg dose achieved SD
  • One 4L sarcoma patient receiving the 30 µg/kg dose achieved SD
  • Two patients (3L sarcoma and 3L metastatic melanoma) achieved SD at the 10 µg/kg dose, with the metastatic melanoma patient maintaining SD for more than a year while escalating to the 60 µg/kg dose.

To date, MDNA11 has demonstrated a favorable tolerability profile in the monotherapy dose escalation segment of the ABILITY study. New data on MDNA11’s safety, pharmacokinetic and pharmacodynamic profiles are expected to be presented at a major medical meeting in the fourth quarter of the calendar year.

About the Phase 1/2 ABILITY Study

The ABILITY (ABeta-only IL-2 ImmunoTherapY) study is designed to assess the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of various doses of intravenously administered MDNA11 in patients with advanced, relapsed, or refractory solid tumors. The trial includes an MDNA11 monotherapy arm, as well as a combination arm designed to evaluate MDNA11 with KEYTRUDA® (pembrolizumab). Approximately 80 patients are expected to be enrolled into the ABILITY Study. Following establishment of the recommended Phase 2 dose (RP2D) and optimal treatment schedule in the study’s dose escalation phase, Medicenna plans to conduct a dose expansion phase that will enroll patients with renal cell carcinoma, melanoma, and other solid tumors in monotherapy and combination settings. For more information, see ClinicalTrials.gov Identifier: NCT05086692.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About Medicenna

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna’s IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws that relate to the future operations of the Company and other statements that are not historical facts including, but not limited to, statements related to the clinical potential, development and tolerability profile of MDNA11 and the expected timing for the presentation of new data related thereto. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions. All statements other than statements of historical fact, included in this release, including, but not limited to, MDNA11’s ultimate treatment potential and statements on the future plans and objectives of the Company, are forward-looking statements that are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest Annual Information Form and Annual Report on Form 20-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

Further Information

For further information about the Company please contact:

Elizabeth Williams, Chief Financial Officer, 416-648-5555, [email protected]   

Investor Contact

For more investor information, please contact:

Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, [email protected]



New Pantry and Storage Jars from the Makers of Ball® Home Canning Products Make Easy Pantry Organization Possible

PR Newswire

Organization and home expert Kim Bui teams up with the brand to provide expert tips, product solutions and blueprints for organizing the most common pantry types


ATLANTA
, Sept. 28, 2022 /PRNewswire/ — Newell Brands, the maker of Ball® home canning products, are adding new Ball® Stack & Store Jars to its pantry and storage collection, designed to take the guesswork out of organization. To celebrate the launch, the brand is partnering with organization, DIY and home design expert Kim Bui (@xomyhome) to create a series of three easy-to-use pantry blueprints, showing people how to mix and match jars for the perfect pantry configuration that’s customizable based on the space they have available.

Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9011053-new-pantry-and-storage-jars-from-makers-of-ball

The makers of Ball® home canning products are adding new Ball® Stack & Store Jars to its pantry and storage collection. Ball® Stack & Store Jars are airtight and stackable, providing space-efficient organization for all pantry needs.

The blueprints tackle three of the most common pantry types – open shelf, cabinet and closet – and outline the optimal layout, number of jars and sizes needed and examples of pantry staples to store inside. Each blueprint features the new Ball® Stack & Store Jars, winner of Good Housekeeping®  magazine’s 2022 Cleaning & Organizing Awards, along with Ball® Storage Latch Jars and Ball® Jars with Wooden Lids.

“Many people know Ball® Jars for canning, but our pantry and storage jars go far beyond just keeping contents fresh – they also make organizing a breeze,” said Kris Malkoski, Business Unit CEO, Writing and Food  at Newell Brands. “We know pantry organization can be challenging and people often don’t know where to start, so we wanted to provide customers with simple solutions. With their versatile and space-saving design, our jars make it easier than ever for our customers to turn their pantry goals into a reality.”


Kim Bui’s Top 5 Pantry Organization Tips
Paired with her pantry blueprints designs, Kim is also sharing five best practices for easy pantry organization.

  • Be transparent: Use clear, airtight containers, such as Ball® pantry and storage jars, to keep dry foods fresh longer and visible for easy access and a clean, streamlined look.
  • Categorize and organize: Group items based on your family’s lifestyle. Categories could be as simple as baking essentials and sweets or more personalized like weeknight meals and kid-friendly foods.
  • Label generously: When emptying dry food items into clear jars, label it with the name of the food item and be sure to include expiration date, especially for items that are not consumed often.
  • Leverage vertical space: Stackable storage items like the Ball® Stack & Store Jars allow for better grouping and space utilization. Risers are also great for items like spices and canned goods to provide a better vantage point of what’s available.
  • Place items with access in mind: Put frequently used items where they can be easily accessed. For families with children, place items such as cereal and bread within eye level and reach, while placing items such as candy and cleaning products in harder-to-reach places to keep young children from accessing them.

Now available at retailers including Target, Walmart, Kroger and more, Ball® Stack & Store Jars are airtight and stackable, providing space-efficient organization for all pantry, cabinet and countertop needs. These jars are an ideal solution for dry goods and can be used for storage and décor throughout the home. The 360-degree crystal-clear clarity and super wide mouth opening make it easy to see and access what’s inside.

The new jars join the existing line of Ball® pantry and storage jars including Storage Latch Jars that feature a durable latch system that creates an airtight seal and a wide mouth opening that offers an easy look at what’s inside. For those looking to elevate the look of the classic Mason Jars inside their pantries or open shelves, Wooden Lids are the perfect decorative accent.

More information on the Ball® pantry and storage jars can be found on ballmasonjars.com.


About Ball®


Home Canning Products

The production of the first Ball® branded glass jar in 1884 by the Ball Brothers Glass Manufacturing Company in Buffalo, New York marked the beginning of a fascinating history. Over 135 years later, their brand  has grown world-wide and that many know and love.  The Ball® logo and Ball®  trademarks are owned by Ball Corporation and used under license by Rubbermaid Incorporated.  Rubbermaid Incorporated’s Ball® brand home canning products are part of Newell Brands’ global portfolio of brands and products.


About Newell Brands


Newell Brands (NASDAQ: NWL) is a leading global consumer goods company with a strong portfolio of well-known brands, including Rubbermaid, FoodSaver, Calphalon, Sistema, Sharpie, Paper Mate, Dymo, EXPO, Elmer’s, Yankee Candle, Graco, NUK, Rubbermaid Commercial Products, Spontex, Coleman, Campingaz, Oster, Sunbeam and Mr. Coffee. Newell Brands’ beloved, planet friendly brands enhance and brighten consumers lives at home and outside by creating moments of joy, building confidence and providing peace of mind.  

This press release and additional information about Newell Brands are available on the company’s website, https://www.newellbrands.com/.

Cision View original content:https://www.prnewswire.com/news-releases/new-pantry-and-storage-jars-from-the-makers-of-ball-home-canning-products-make-easy-pantry-organization-possible-301635528.html

SOURCE Newell Brands

BYND Cannasoft Enterprises Inc. Launches Beta Test for Managing Farms CRM Platform at Israel’s Weizmann Institute of Science

Beta version of software provided as SAAS includes BYND Cannasoft’s proprietary C.R.M. System – Job Management (BENEFIT), as well as a module system for managing farms and greenhouses with varied crops (CANNASOFT)

VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND” or the “Company”) announced that its subsidiary BYND – Beyond Solutions Ltd. has signed an agreement with the Weizmann Institute of Science for the use of its proprietary software. Under the terms of the agreement, the Weizmann Institute of Science will use a beta version of the software provided as SAAS. The beta version will include BYND Cannasoft Enterprises’ C.R.M. System – Job Management (BENEFIT), as well as a module system (CANNASOFT) for managing farms and greenhouses with varied crops. BYND Cannasoft Enterprises will grant the Weizmann Institute a permit to use the license free of charge for a period of one year, after which the institute will have the right to extend the agreement and the Company will be paid a rate according to the agreement.

The Weizmann Institute of Science is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It has a long history of investigation and discovery rooted in a mission of advancing science for the benefit of humanity. In parallel, it educates a substantial proportion of Israel’s scientific leadership and advances science literacy in schools and among the public. The Weizmann Institute of Science has pioneered research using CBD to treat conditions as diverse as glaucoma, Parkinson’s, chemotherapy side effects, MS, and Crohn’s, while using advanced tools, like CRISPR gene editing, to further understand cannabis.

Yftah Ben Yaackov, CEO and a Director of BYND, said, “This is an extremely important step in the development of BYND Cannasoft Enterprises medical cannabis software since the Weizmann Institute has many greenhouses of various types that can cover all the development possibilities of the software in the coming year. We are honored to have the opportunity to beta test our cloud-based platform with a world-class institution like the Weizmann Institute of Science.”

BYND Cannasoft Enterprises will perform updates and continue to develop its software based on the conclusions and applications of the customer’s interactions. BYND Cannasoft expects additional revenues from the use of the software licenses and from dedicated development for the benefit of the Weizmann Institute of Science.

About the Weizmann Institute of Science

The Weizmann Institute of Science in Israel is one of the world’s top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, Weizmann Institute’s scientists are advancing research on the human brain, artificial intelligence, computer science and encryption, astrophysics, and particle physics, and are tackling diseases such as cancer, while also addressing climate change through environmental, ocean, and plant sciences.

About BYND Cannasoft Enterprises Inc.  

BYND is an integrated software/cannabis company, based in Israel.   

CRM Software

BYND owns and markets a proprietary customer relationship management (CRM) software product, known as “Benefit CRM”. BYND’s Benefit CRM software enables small and medium‐sized businesses to optimize their day‐to‐day business activities such as sales management, personnel management, marketing, call center activities and asset management. BYND’s next-generation Benefit CRM platform is now ready for BETA testing.

Cannabis CRM

Building on its 20 years of experience in CRM software, BYND has recently begun development of an innovative new CRM platform, designed specifically to serve the needs of the medical cannabis industry. This new platform will be the first of its kind for the medical cannabis field and the Company is confident it will transform the industry into a more organized, accessible, and price transparent market. Data and information collected through the operation of the Cannabis Farm (see below) and the products it produces will allow BYND to test its new Cannabis CRM platform and adjust the platform as necessary. Additionally, operating the Cannabis Farm and selling medical cannabis will bring in additional revenue to further support BYND during the initial roll‐out years of its cannabis CRM platform.

Cannabis Farm

BYND is in the process of securing approval for the transfer of a primary growing license for growing medical cannabis in Israel and intends to construct a 3.7 acre farm facility near Ashkelon Israel, to grow medical cannabis. The Company’s plans include the construction of 4 state of the art greenhouses, housing approximately 2.5 acres of total growing area.  BYND estimates that once fully operational its Cannabis farm facility will be able to produce 7,500kg of raw cannabis each year.  BYND also intends to work with strategic partners to develop and market new, proprietary cannabis-infused products for sale throughout Israel and for export. For Further Information please refer to the information available on the Company’s website: www.cannasoft‐ crm.com, the CSE’s website:  www.thecse.com/en/listings/life‐sciences/bynd‐cannasoft‐enterprises‐inc and on SEDAR: www.sedar.com.  

Gabi Kabazo 
Chief Financial Officer 
Tel: (604) 833‐6820
e‐mail: [email protected]‐crm.com

For Media and Investor Relations, please contact:
David L. Kugelman
(866) 692-6847 Toll Free – U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
[email protected]
Skype: kugsusa

Cautionary Note Regarding Forward‐Looking Statements

This Press Release contains forward‐looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward‐looking statements.. Such statements reflect our current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause our actual results to differ materially from the statements made, including those factors discussed in filings made by us with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. Should one or more of these risks and uncertainties, such as currency and interest rate fluctuations, increased competition, and general economic and market factors, occur or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward‐looking statements, except as required by law. Shareholders are cautioned not to put undue reliance on such forward‐looking statements.

Neither the U.S. Securities and Exchange Commission nor the CSE has reviewed, approved or disapproved the content of this press release.



JPMorgan Chase Kicks Off First-Ever Software Engineering Conference, DEVUP For Engineers By Engineers

JPMorgan Chase Kicks Off First-Ever Software Engineering Conference, DEVUP For Engineers By Engineers

DALLAS–(BUSINESS WIRE)–
Today, JPMorgan Chase kicks off DEVUP, its firmwide software engineering conference for engineers by engineers. In this first, one-of-a-kind technology innovation forum, the financial services firm is bringing together 500 software engineers and data scientists from nearly 30 major cities globally for three action-packed days of engineering excellence.

Discussions of a wide range of research topics, breakout sessions, and hands-on experiences will encourage the firm’s engineers to generate ideas that solve common challenges, discuss technology priorities, and ideate ways to solve complex problems at scale.

“As part of our continued commitment to driving innovation and supporting our talent, we are excited to bring together the leading engineers across our company. This is just one example of how we invest in our talent – providing opportunities for our software engineers and data scientists to build their skills, their networks and to solve complex challenges,” said Lori Beer, Global Chief Information Officer, JPMorgan Chase. “This is a great opportunity for our software engineers to collaborate in person and think into the future. We hope that with this first DEVUP, our engineers are further empowered, energized and challenged to deliver the best capabilities for one of the world’s largest financial services organizations as we continue to execute on our forward-thinking technology strategy.”

Participants will be encouraged to bring their individual perspectives and ideas for solving common strategic challenges. Attendees will discuss ways of accelerating JPMorgan Chase’s continued public cloud migration, building upon the firm’s widespread AI/ML adoption, developing code, and programming to create high quality products and applications. Speakers were carefully selected through an abstract submission process.

During the event, JPMorgan Chase technologists will experience:

  • Collaborative sessions with internal and external industry leaders
  • Personalized learning pathways and experiences
  • Networking opportunities throughout the event

The conference is taking place in-person from September 28-30 at JPMorgan Chase’s Global Technology Center in Dallas.

About JPMorgan Chase

JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $3.8 trillion and operations worldwide. JPMorgan Chase serves millions of consumers in the United States and many of the world’s most prominent corporate, institutional and government clients. With over 55,000 technologists globally and an annual tech spend of $14 billion, JPMorgan Chase is dedicated to improving the design, analytics, development, coding, testing and application programming that goes into creating high quality software and new products. Visit http://www.jpmorganchase.com/tech for more information.

MEDIA CONTACT:

Jennifer Lavoie

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Professional Services Data Management Engineering Technology Manufacturing Software Finance

MEDIA:

Logo
Logo

Zhongchao Inc. Establishes Chongqing Xinjiang Pharmaceutical Co., Ltd. to Improve Patient Access to Medications

PR Newswire


SHANGHAI
, Sept. 28, 2022 /PRNewswire/ — Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced the establishment of Chongqing Xinjiang Pharmaceutical Co., Ltd. (“Xinjiang Pharmaceutical”) which mainly engages in pharmaceutical import and export trade, OME (original equipment manufacturer) production, medical consumables operation, and pharmaceutical internet services. Zhongchao expects to further improve and complement its business model of “Medical-Pharmaceutical-Patient” as Xinjiang Pharmaceutical plays an important role in supplying quality medications for patients.

The Company has implemented a few steps in extending its business model from “Medical-Pharmaceutical” to “Medical-Pharmaceutical-Patient” in order to meet the increasing demands of patient-oriented healthcare in China. Followed by the launch of Zhixun Internet Hospital to provide standardized internet healthcare services for patients with oncology or other major diseases, Zhongchao established Xinjiang Pharmaceutical to aim at realizing medications accessibility and affordability for those patients. Xinjiang Pharmaceutical plans to cooperate with Zhixun Internet Hospital and other internet hospitals to build a 2B2C (to business and to customer) pharmaceutical procurement platform, aiming to streamline the delivery of medicines from pharmaceutical factories to retail ends. This approach will enable Xinjiang Pharmaceutical to supply domestic and international high-quality and cost-effective drugs, improving drug accessibility and lowering medication cost.  

Weiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, “We are excited to announce the establishment of Xinjiang Pharmaceutical, as it is another important step for us to improve our model of “Medical-Pharmaceutical-Patient” in the field of oncology and other major diseases. We expect to leverage our established networks and resources with pharmaceutical companies to form a pharmaceutical service system covering the whole industrial chain to enhance drug accessibility and affordability for patients. We are committed to contributing to the improved patient experience.”

About Zhongchao Inc.

Zhongchao Inc. is an offshore holding company incorporated in the Cayman Islands. It conducts operations in China through the contractual arrangements between its wholly owned subsidiary and PRC operating entities. Zhongchao Inc. is a platform-based internet technology company offering services to patients with oncology and other major diseases. The PRC operating entities provide online healthcare information, professional training and educational services to healthcare professionals under their “MDMOOC” platform (www.mdmooc.org), offer patient management services in the professional field of tumor and rare diseases through Zhongxin, offer internet healthcare services through Zhixun Internet Hospital, and pharmaceutical services through Xinjiang Medical and operate an online information platform, Sunshine Health Forums, to general public. More information about the Company can be found at its investor relations website at http://izcmd.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the professional training and educational services market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

At the Company: Pei Xu, CFO
Email: [email protected]
Phone: +86 21-3220-5987

Investor Relations: Sherry Zheng  
Weitian Group LLC
Email: [email protected]
Phone: +1 718-213-7386

Cision View original content:https://www.prnewswire.com/news-releases/zhongchao-inc-establishes-chongqing-xinjiang-pharmaceutical-co-ltd-to-improve-patient-access-to-medications-301635518.html

SOURCE Zhongchao Inc.

AGS Takes its Portfolio to A New Level at the 2022 Global Gaming Expo in Las Vegas

PR Newswire


LAS VEGAS
, Sept. 28, 2022 /PRNewswire/ — AGS (NYSE: AGS) or (the “Company”) announced today that it will showcase a new level of product diversity and innovation in all three of its business divisions: Electronic Gaming Machines (“EGM’s”), Table Products, and Interactive at the 2022 Global Gaming Expo (“G2E”) held Oct. 11 – 13 in Las Vegas, Nevada.

In booth 1253, the Company will leverage the theme “Level Up,” to emphasize a new era of its expanding product portfolio. Led by the debut of a next-generation cabinet, Spectra UR43™, alongside 37 new slot games displayed across multiple form factors and an industry-leading table games lineup, the showcase truly reflects the Company’s team of unmatched talent and recent studio expansions across the globe.

“We believe that it takes exceptional people to make exceptional products, and we’ve seen this in action,” said AGS President and Chief Executive Officer David Lopez. “Our unique culture and ability to attract and retain some of the brightest minds in the business have allowed us to innovate and expand into new product segments and new markets. Whether it’s the continued depth of content for the core and premium markets, the extension of successful game themes and table progressives, the introduction of more feature sets and bet varieties, or further diversification in cabinet families and card shufflers, it will be very apparent at G2E that we’ve leveled up our offerings across the board.  We are excited to welcome our customers, investors, and other key stakeholders to the show to see how far we’ve come as a company and show off our team’s hard work.”

In addition, AGS’ Table Products division will take it to the next level with the display of top-performing products from the expansion of its award-winning progressives to the launch of its single-deck Pax S® shuffler, and the strategic acquisition of Lucky Lucky®, a blackjack side bet, in early 2022.

AGSi, the Company’s Interactive division, plans to further leverage AGS’ extensive slot content portfolio, consisting of a variety of proven land-based slot titles, to further cement the Company’s position as a leading provider of slot content to regulated real-money gaming operators across the globe.

AGS’ product highlights at G2E underscore the transformation the Company has undergone over the past few years as a result of its steadfast investments in R&D, and include:

  • The debut of a new EGM cabinet:
    Spectra UR43™ features a 43″ UltraHD 4K portrait monitor, game-controlled eclipse lighting, and V-Sync technology for seamless video linking capabilities when machines are banked together. Spectra is expected to debut with the deepest content pipeline of any new AGS cabinet launch, including new concepts and extensions of AGS’ player-favorites, supporting both Class II and Class III end markets.
  • Entrance into the high denomination product segment: AGS’ four high-denomination, three-reel video games, Mega Diamond™, Gold Inferno®, Platinum 8x8x8x™, and 8x Crystal Bells™, are blazing across casino floors. The new titles allow AGS to offer additional bet varieties and appeal to a wide range of players.
  • A dynamic game library supporting multiple markets: Fifty slot machines and 37 titles fill the booth to showcase the breadth and depth of AGS’ game portfolio, which supports the Class II, Class III, Historical Horse Racing (“HHR”), LatAm, and online markets.
  • Industry-leading table products: AGS’ award-winning table progressive, Bonus Spin Xtreme™, continues to evolve by offering a new trigger for craps and an additional Mystery Spin bonus feature, furthering its ability to engage players and link to multiple game types on a floor.

About AGS

AGS is a global company focused on creating a diverse mix of entertaining gaming experiences for every kind of player. Our roots are firmly planted in the Class II Native American gaming market, but our customer-centric culture and growth have helped us branch out to become a leading all-inclusive commercial gaming supplier. Powered by high-performing Class II and Class III slot products, an expansive table products portfolio, real-money gaming platforms and content, highly rated social casino solutions for operators and players, and best-in-class service, we offer an unmatched value proposition for our casino partners. Learn more at www.playags.com.


About Global Gaming Expo

Global Gaming Expo (G2E) is the world’s premier gathering of commercial and tribal gaming professionals. For 20 years, G2E has convened the global gaming industry to discover cutting-edge technology, connect with peers and industry experts, and access expert education. Learn more at www.globalgamingexpo.com.

Media Contact:
Julia Boguslawski, Chief Marketing Officer
[email protected]

Nikki Davis, Director of Marketing & Communications
[email protected]

AGS Investor Contact:
Brad Boyer, Senior Vice President of Investor Relations & Corporate Operations
[email protected] 

©2022 AGS LLC. All® notices signify marks registered in the United States. All ™ and ℠ notices signify trademarks, which are not registered on any country-wide basis. Products referenced herein are sold by AGS LLC or other subsidiaries of PlayAGS, Inc. 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ags-takes-its-portfolio-to-a-new-level-at-the-2022-global-gaming-expo-in-las-vegas-301635102.html

SOURCE AGS